Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* histologically confirmed esophageal cancer (squamous carcinoma) measurable, non-metastatic disease~* no previous cancer therapy (chemotherapy, radiotherapy or resection)~* life expectancy \> 3 months~* age \> 18 years~* WHO Status ≤ 1~* Intended curative resection according to evaluation of an experienced surgeon~* Negative pregnancy blood test at screening but not earlier than 72 hours prior to start of chemotherapy for women with child bearing potential~* Adequate haematologic function and liver and renal function: neutrophils \> 1.5×109/L; thrombocytes \> 100×109/L; haemoglobin \> 10 g/dl, creatinine clearance \> 60 ml/min (calculated according to Cockroft and Gault), total bilirubin \< 1.0×UNL; AST and ALT \< 1.5×UNL, AP \< 2.5×UNL~* Complete staging within 3 weeks prior to start of treatment (CT-scan of thorax and abdomen, endosonography, gastroscopy)~* Ability to keep appointments and follow the study protocol~* By CT-scan, endoscopy or endosonography measurable or evaluable disease~Exclusion Criteria:~* Former therapy of cancer (operation, chemo- or radiotherapy)~* Diagnosis of another cancer in the last 5 years prior to study entry which has not been cured by operation only (exception in-situ-carcinoma of the cervix or cured non-melanomatose skin cancer)~* Known contraindication to the planned chemotherapeutics~* Presence of distant metastases~* Anamnestic known serious disease or other concomitant diseases that affect participation in this study, such as:~oInstable cardiac disease: symptomatic heart failure, symptomatic coronary artery disease, ventricular cardiac arrhythmia not well controlled with medication, myocardial infarction or resuscitation within 6 month before study oActive infection necessitating systemic therapy or uncontrolled infection oInterstitial lung diseases (for example: pneumonitis or fibrosis of the lung) and indication for interstitial lung disease in chest x-ray or CT-scan respectively oActive inflammatory bowel disease or other bowel diseases which provoke chronic diarrhea (defined as \> 4 bowel movements per day) oNeurological or psychiatric disease including dementia, epilepsy or untreated, symptomatic brain metastases oLimited hearing ability~* Presence of upper GI obstruction, leading to inability to swallow ground tablets~* Presence of acute or chronic systemic infection~* Presence of a bowel obstruction within the last 30 days~* Pregnant or lactating women or women with child bearing potential and men without adequate contraception (high effective contraception, defined as Pearl Index \< 1) like birth control pill, hormone spiral, hormone implant, transdermal patch, a combination of two barrier methods (condom and diaphragm), realized sterilization or sexual abstinence during the study and at least for 3 months after the last infusion~* Any other situation which may lead to an unacceptable high risk for the patient, when he participates in the study~* Parallel treatment in another clinical study or prior participation in this study~* Treatment with any other therapy against the tumor or any parallel radiation~* Symptomatic peripheral neuropathy NCI-CTCAE degree \> 2~* Intolerance to the study medication~* Detention in a psychiatric unit or imprisonment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Preoperative chemotherapy followed by surgery (Type: ACTIVE_COMPARATOR): None
- Perioperative chemotherapy with surgery (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).